Method of diagnosing and monitoring malignant breast carcinomas

Details Method of diagnosing and monitoring malignant breast carcinomas Method of diagnosing and monitoring malignant breast carcinomas

2005-12-06

2005-12-06

Siew, Jeffrey (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S004000, C435S007100, C435S007200, C435S007210, C435S007920, C435S007930, C435S007940, C436S501000, C436S063000, C436S064000

Reexamination Certificate

active

06972180

ABSTRACT:
A panel of biomarkers for the diagnosis and treatment of breast cancer was examined in the saliva of a cohort of 1) healthy women, 2) women with benign lesions of the breast and 3) women with diagnosed breast cancer. Recognized tumor markers c-erbB-2 (erb), cancer antigen 15-3 (CA 15-3), and tumor suppresser oncogene protein 53 (p53) were found in the saliva of all three groups of women. The levels of erb and CA 15-3 in the cancer patients evaluated, however, were significantly higher than the salivary levels of healthy controls and benign tumor patients. Conversely, pantropic p53 levels were higher in controls as compared to those women with breast cancer and those with benign tumors.

REFERENCES:
patent: 5401638 (1995-03-01), Carney et al.
patent: 5512657 (1996-04-01), Van Aken et al.
patent: 5527676 (1996-06-01), Vogelstein et al.
patent: 5769074 (1998-06-01), Barnhill et al.
patent: 5840889 (1998-11-01), Cavalieri et al.
patent: 5858365 (1999-01-01), Faller
patent: 5858683 (1999-01-01), Keesee et al.
patent: 6294349 (2001-09-01), Streckfus et al.
patent: WO 91/02062 (1991-02-01), None
patent: WO 00/44403 (2000-08-01), None
Streckfus et al., The presencre of CA 15-3, c-erbB-2, cathepsin-D, EGFR, WAF1, and p53 in saliva among women with benign and malignant breast disease., The Journal of Dental Research, vol. 77, pp. 286, Abstract# 1437, Jan. 1998.
Streckfus, et al. “The Presence of CA 15-3, c-erB-2, Cathespin-D, EGFR, WAF1 and p53 in Saliva Among Women with Benign and Malignant Tumors.”Journal of Dental Research,Jan. 30, 1998, p. 285, #1437, vol. 77. University of Mississippi Medical Center, Jackson, MS.
Dobrosielski-Vergona, K., Biology of University of Pittsburgh, Pittsburgh, Pennsylvania, PA, CRC Press, Inc., Boca Raton, FL.
Baum, B., “Age Changes in Salivary Glands and Salivary Secretion,” Chapter 8:Geriatric Dentistry —A Textbook of Oral Gerontology;Edited by: Holm-Pedersen, P., and Loe, H., The C.V. Mosby Company, St. Louis; Washington, DC; Toronto.
Cook, D.I., et al., “Secretion by the Major Salivary Glandsp”, Chapter 26:Physiology of the Gastrointestinal Tract,1994, pp. 1061-1117, Third Edition, Raven Press, New York.
Sreebny, L., “The Salivary System”,Dept. of Oral Biology and Pathology, pp. 128-131, State University of New York at Stony Brook, Stony Brok, New York, CRC Press, Inc., Boca Raton, Florida.
Chen, D., “Saliva and Serum CA 125 Assays for Detecting Malignant Ovarian Tumors”,Dept. of Obstetrics and Gynecology, First Affiliated Hospital, Human Medical University, People's Republic of China, and theDept. of Obstetrics and Gynecology, Yale University, School of Medicine, New Haven, Connecticut, Apr. 1990,. pp. 701-703, vol. 75, No. 4.
Mandel, I., “Sialochemistry in Diseases and Clinical Situations Affecting Salivary Glands”,CRC Critical Reviews in Clinical Laboratory Sciences, Sep. 1980, pp. 321-366, New York, New York.

Affiliated with

Also associated with

Rating

Method of diagnosing and monitoring malignant breast carcinomas does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of diagnosing and monitoring malignant breast carcinomas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of diagnosing and monitoring malignant breast carcinomas will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3513779